share_log

TG Therapeutics (NASDAQ:TGTX) Delivers Shareholders Solid 15% CAGR Over 5 Years, Surging 6.6% in the Last Week Alone

TG Therapeutics (NASDAQ:TGTX) Delivers Shareholders Solid 15% CAGR Over 5 Years, Surging 6.6% in the Last Week Alone

tg therapeutics(納斯達克:TGTX)在過去5年中爲股東提供了堅實的15%複合年增長率,僅在上週就暴漲了6.6%。
Simply Wall St ·  06/22 20:01

When you buy shares in a company, it's worth keeping in mind the possibility that it could fail, and you could lose your money. But on a lighter note, a good company can see its share price rise well over 100%. Long term TG Therapeutics, Inc. (NASDAQ:TGTX) shareholders would be well aware of this, since the stock is up 104% in five years. Also pleasing for shareholders was the 14% gain in the last three months.

當你買下一家公司的股票時,有可能失敗並且失去你的資金,所以需要記住這一點。但是,好的公司股價可以漲超過100%。長揸TG Therapeutics,Inc. (納斯達克:TGTX)的股東應該清楚這一點,因爲股價在過去五年中上漲了104%。股東最近三個月也受益於14%的漲幅。

The past week has proven to be lucrative for TG Therapeutics investors, so let's see if fundamentals drove the company's five-year performance.

過去一週對TG Therapeutics的投資者來說是有利可圖的,因此我們來看看基本面是否推動了公司的五年表現。

In his essay The Superinvestors of Graham-and-Doddsville Warren Buffett described how share prices do not always rationally reflect the value of a business. One way to examine how market sentiment has changed over time is to look at the interaction between a company's share price and its earnings per share (EPS).

在他的文章《格雷厄姆和多德斯維爾超級投資者》中,禾倫·巴菲特描述了股票價格並不總是反映公司價值的合理方式。考慮市場對公司的看法如何發生變化的一個不完美但簡單的方法是將每股收益(EPS)的變化與股價的變動進行比較。股票價格並不總是反映公司價值的合理方式禾倫·巴菲特曾稱,股票價格並不總是合理地反映了企業的價值。檢查市場情緒如何隨時間變化的一種方法是查看公司股價和每股收益(EPS)之間的互動。

During the five years of share price growth, TG Therapeutics moved from a loss to profitability. Sometimes, the start of profitability is a major inflection point that can signal fast earnings growth to come, which in turn justifies very strong share price gains.

在五年的股價增長中,TG Therapeutics從虧損轉向盈利。有時,盈利的開始是一個重要的拐點,可以預示着快速盈利增長的到來,從而有助於強勁的股價上漲。

You can see how EPS has changed over time in the image below (click on the chart to see the exact values).

您可以在下面的圖片中查看每股收益如何隨時間變化(單擊圖表以查看確切的價值)。

earnings-per-share-growth
NasdaqCM:TGTX Earnings Per Share Growth June 22nd 2024
納斯達克CM:TGTX每股收益增長於2024年6月22日

We like that insiders have been buying shares in the last twelve months. Even so, future earnings will be far more important to whether current shareholders make money. This free interactive report on TG Therapeutics' earnings, revenue and cash flow is a great place to start, if you want to investigate the stock further.

我們喜歡內部人在過去十二個月中購買股票。即便如此,未來的收益才是決定當前股東是否賺錢的更重要因素。如果您想進一步研究該股票,可以參考TG Therapeutics的財務報告,包括收益、營業收入和現金流。

A Different Perspective

不同的觀點

While the broader market gained around 26% in the last year, TG Therapeutics shareholders lost 25%. However, keep in mind that even the best stocks will sometimes underperform the market over a twelve month period. Longer term investors wouldn't be so upset, since they would have made 15%, each year, over five years. If the fundamental data continues to indicate long term sustainable growth, the current sell-off could be an opportunity worth considering. While it is well worth considering the different impacts that market conditions can have on the share price, there are other factors that are even more important. To that end, you should be aware of the 2 warning signs we've spotted with TG Therapeutics .

儘管廣泛市場在過去一年中上漲了約26%,TG Therapeutics的股東卻虧損了25%。然而,請記住,即使是最好的股票有時也會在十二個月的時期內表現不佳。長期投資者不會那麼失落,因爲他們在五年中每年都獲得了15%的利潤。如果基本數據繼續表明具有長期可持續增長的潛力,當前的賣出浪潮可能是值得考慮的機會。雖然考慮市場條件對股價的不同影響非常值得,但有其他更重要的因素。因此,您應該注意我們在TG Therapeutics中發現的2個警告信號。

If you like to buy stocks alongside management, then you might just love this free list of companies. (Hint: most of them are flying under the radar).

如果您喜歡與管理層共同購買股票,那麼您可能會喜歡這個免費的公司列表(提示:大多數公司沒有受到關注)。

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on American exchanges.

請注意,本文所引述的市場回報反映了目前在美國交易所上市的股票的市場加權平均回報。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對本文有反饋?關於內容有所顧慮?直接和我們聯繫。或者,發送電子郵件至editorial-team (at) simplywallst.com。
這篇文章是Simply Wall St的一般性文章。我們根據歷史數據和分析師預測提供評論,只使用公正的方法論,我們的文章並不意味着提供任何金融建議。文章不構成買賣任何股票的建議,也不考慮您的目標或您的財務狀況。我們的目標是帶給您基本數據驅動的長期關注分析。請注意,我們的分析可能不考慮最新的價格敏感公司公告或定性材料。Simply Wall St沒有任何股票頭寸。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

對本文有反饋?關於內容有所顧慮?直接和我們聯繫。或者發送電子郵件至editorial-team@simplywallst.com。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論